Moses S. Raj

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 613 citations · Full text

Medicine, Oncology, Pharmacology +12

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo et al. · The Lancet Oncology · 2019 · 284 citations · Full text

Medicine, Oncology, Pharmacology +13

Microsatellite Instability (MSI) as an Independent Predictor of Pathologic Complete Response (PCR) in Locally Advanced Rectal Cancer

Shaakir Hasan, Paul Renz, Rodney E. Wegner et al. · Annals of Surgery · 2018 · 152 citations · Full text

Medicine, Oncology, Surgery +17

Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

Philippe Merle, Jean‐Frédéric Blanc, Jean–Marc Phelip et al. · ˜The œLancet. Gastroenterology & hepatology · 2019 · 61 citations · Full text

Pharmacy, Oncology, Pharmacology +17

PI3K/mTOR Dual Inhibitor, LY3023414, Demonstrates Potent Antitumor Efficacy Against Esophageal Adenocarcinoma in a Rat Model

Ali H. Zaidi, Juliann E. Kosovec, Daisuke Matsui et al. · Annals of Surgery · 2016 · 36 citations

Medicine, Oncology, Pharmacology +17